BioCentury
ARTICLE | Company News

Deciphera cancer news

October 15, 2012 7:00 AM UTC

Deciphera said it plans to transition to an oncology drug development company from an oncology discovery company. The company will initially focus on developing its rebastinib ( DCC-2036) and DCC-2701 drug candidates discovered using the company's switch pocket kinase inhibitor technology. Rebastinib, a BCR-ABL tyrosine kinase inhibitor, has completed Phase I testing to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), with Phase Ib testing in solid tumors slated to begin in April 2013. DCC-2701 is an oral small molecule targeting VEGF receptor 2 ( KDR/Flk-1; VEGFR-2) and c-Met receptor tyrosine kinase. DCC-2701 is expected to enter Phase I testing for highly invasive and metastatic cancers next year. Deciphera's pipeline also includes DCC-2721, which is a backup compound to DCC-2701. ...